{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:20Z","timestamp":1707524480405},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,2]]},"DOI":"10.7759\/cureus.21834","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T13:17:54Z","timestamp":1643807874000},"source":"Crossref","is-referenced-by-count":0,"title":["Idiopathic Symptoms Resolved by Pharmacogenomics-Enriched Comprehensive Medication Management: A Case Report"],"prefix":"10.7759","author":[{"given":"April","family":"Prather","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aissa","family":"Aifaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A","family":"Shaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2016.06.005","article-title":"A synopsis on aging-theories, mechanisms and future prospects","volume":"29","author":"da Costa JP","year":"2016","unstructured":"da Costa JP, Vitorino R, Silva GM, Vogel C, Duarte AC, Rocha-Santos T. A synopsis on aging-theories, mechanisms and future prospects. Ageing Res Rev. 2016, 29:90-112. 10.1016\/j.arr.2016.06.005","journal-title":"Ageing Res Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12601","article-title":"Molecular and physiological manifestations and measurement of aging in humans","volume":"16","author":"Khan SS","year":"2017","unstructured":"Khan SS, Singer BD, Vaughan DE. Molecular and physiological manifestations and measurement of aging in humans. Aging Cell. 2017, 16:624-33. 10.1111\/acel.12601","journal-title":"Aging Cell"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2003.07.003","article-title":"Fatigue and aging","volume":"48","author":"Tralongo P","year":"2003","unstructured":"Tralongo P, Respini D, Ferra\u00f9 F. Fatigue and aging. Crit Rev Oncol Hematol. 2003, 48:S57-64. 10.1016\/j.critrevonc.2003.07.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2016.11.034","article-title":"Cognitive challenges, aging, and neuromuscular fatigue","volume":"170","author":"Shortz AE","year":"2017","unstructured":"Shortz AE, Mehta RK. Cognitive challenges, aging, and neuromuscular fatigue. Physiol Behav. 2017, 170:19-26. 10.1016\/j.physbeh.2016.11.034","journal-title":"Physiol Behav"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03415.x","article-title":"Medication errors: definitions and classification","volume":"67","author":"Aronson JK","year":"2009","unstructured":"Aronson JK. Medication errors: definitions and classification. Br J Clin Pharmacol. 2009, 67:599-604. 10.1111\/j.1365-2125.2009.03415.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5888\/pcd10.120308","article-title":"Multiple chronic conditions among US adults who visited physician offices: data from the National Ambulatory Medical Care Survey, 2009","volume":"10","author":"Ashman JJ","year":"2013","unstructured":"Ashman JJ, Beresovsky V. Multiple chronic conditions among US adults who visited physician offices: data from the National Ambulatory Medical Care Survey, 2009. Prev Chronic Dis. 2013, 10:E64. 10.5888\/pcd10.120308","journal-title":"Prev Chronic Dis"},{"key":"ref7","article-title":"Multiple chronic conditions among adults aged 45 and over: trends over the past 10 years","author":"Freid VM","year":"2012","unstructured":"Freid VM, Bernstein AB, Bush MA. Multiple chronic conditions among adults aged 45 and over: trends over the past 10 years. NCHS Data Brief. 2012, 1-8.","journal-title":"NCHS Data Brief"},{"key":"ref8","unstructured":"Chronic conditions. (2021). Accessed. December 14, 2021: https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Chronic-Conditions\/CC_Main."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-013-0007-6","article-title":"Drug treatment of acute ischemic stroke","volume":"13","author":"Bansal S","year":"2013","unstructured":"Bansal S, Sangha KS, Khatri P. Drug treatment of acute ischemic stroke. Am J Cardiovasc Drugs. 2013, 13:57-69. 10.1007\/s40256-013-0007-6","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0157-2","article-title":"Drug-related problems and medication reviews among old people with dementia","volume":"18","author":"Pfister B","year":"2017","unstructured":"Pfister B, Jonsson J, Gustafsson M. Drug-related problems and medication reviews among old people with dementia. BMC Pharmacol Toxicol. 2017, 18:52. 10.1186\/s40360-017-0157-2","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2016.09.035","article-title":"The healthy aging research network: modeling collaboration for community impact","volume":"52","author":"Belza B","year":"2017","unstructured":"Belza B, Altpeter M, Smith ML, Ory MG. The healthy aging research network: modeling collaboration for community impact. Am J Prev Med. 2017, 52:S228-32. 10.1016\/j.amepre.2016.09.035","journal-title":"Am J Prev Med"},{"key":"ref12","unstructured":"Healthy ageing and functional ability. (2020). Accessed. December 14, 2021: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/ageing-healthy-ageing-and-functional-ability."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026119","article-title":"The structure and predictive value of intrinsic capacity in a longitudinal study of ageing","volume":"9","author":"Beard JR","year":"2019","unstructured":"Beard JR, Jotheeswaran AT, Cesari M, de Carvalho IA. The structure and predictive value of intrinsic capacity in a longitudinal study of ageing. BMJ Open. 2019, 9:e026119. 10.1136\/bmjopen-2018-026119","journal-title":"BMJ Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/08870446.2014.904862","article-title":"Healthy ageing from the perspective of older people: a capability approach to resilience","volume":"30","author":"Stephens C","year":"2015","unstructured":"Stephens C, Breheny M, Mansvelt J. Healthy ageing from the perspective of older people: a capability approach to resilience. Psychol Health. 2015, 30:715-31. 10.1080\/08870446.2014.904862","journal-title":"Psychol Health"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00133","article-title":"Frailty and intrinsic capacity: two distinct but related constructs","volume":"6","author":"Belloni G","year":"2019","unstructured":"Belloni G, Cesari M. Frailty and intrinsic capacity: two distinct but related constructs. Front Med. 2019, 6:133. 10.3389\/fmed.2019.00133","journal-title":"Front Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/gm4","article-title":"The twin questions of personalized medicine: who are you and whom do you most resemble?","volume":"1","author":"Kohane IS","year":"2009","unstructured":"Kohane IS. The twin questions of personalized medicine: who are you and whom do you most resemble?. Genome Med. 2009, 1:4. 10.1186\/gm4","journal-title":"Genome Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198701293160505","article-title":"Decision analysis","volume":"316","author":"Pauker SG","year":"1987","unstructured":"Pauker SG, Kassirer JP. Decision analysis. N Engl J Med. 1987, 316:250-8. 10.1056\/NEJM198701293160505","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2019.1678568","article-title":"Polypharmacy: a healthcare conundrum with a pharmacogenetic solution [PREPRINT]","author":"Sharp CN","year":"2019","unstructured":"Sharp CN, Linder MW, Valdes R Jr. Polypharmacy: a healthcare conundrum with a pharmacogenetic solution [PREPRINT]. Crit Rev Clin Lab Sci. 2019, 1-20. 10.1080\/10408363.2019.1678568","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1597706","article-title":"The role of pharmacogenomics in adverse drug reactions","volume":"12","author":"Cacabelos R","year":"2019","unstructured":"Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019, 12:407-42. 10.1080\/17512433.2019.1597706","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.2019.1716","article-title":"Beyond drugs: the evolution of genes involved in human response to medications","volume":"286","author":"Fuselli S","year":"2019","unstructured":"Fuselli S. Beyond drugs: the evolution of genes involved in human response to medications. Proc Biol Sci. 2019, 286:20191716. 10.1098\/rspb.2019.1716","journal-title":"Proc Biol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling MV","year":"2015","unstructured":"Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015, 526:343-50. 10.1038\/nature15817","journal-title":"Nature"},{"key":"ref22","unstructured":"Table of pharmacogenetic associations. (2020). Accessed. December, 14, 2021: https:\/\/www.fda.gov\/medical-devices\/precision-medicine\/table-pharmacogenetic-associations."},{"key":"ref23","unstructured":"Table of pharmacogenomic biomarkers in drug labeling. (2020). Accessed. December, 14, 2021: https:\/\/www.fda.gov\/drugs\/science-and-research-drugs\/table-pharmacogenomic-biomarkers-drug-labeling."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Link E","year":"2008","unstructured":"Link E, Parish S, Armitage J, et al.. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008, 359:789-99. 10.1056\/NEJMoa0801936","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora D","year":"2009","unstructured":"Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009, 54:1609-16. 10.1016\/j.jacc.2009.04.053","journal-title":"J Am Coll Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells","volume":"15","author":"Kameyama Y","year":"2005","unstructured":"Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005, 15:513-22. 10.1097\/01.fpc.0000170913.73780.5f","journal-title":"Pharmacogenet Genomics"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.96","article-title":"A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics","volume":"94","author":"Blake CM","year":"2013","unstructured":"Blake CM, Kharasch ED, Schwab M, Nagele P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther. 2013, 94:394-9. 10.1038\/clpt.2013.96","journal-title":"Clin Pharmacol Ther"},{"key":"ref28","article-title":"Metoprolol Therapy and CYP2D6 Genotype","author":"Dean L","year":"2012","unstructured":"Dean L. Metoprolol Therapy and CYP2D6 Genotype. Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ (ed): National Center for Biotechnology Information (US), Bethesda, MD; 2012."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.07.004","article-title":"Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study","volume":"78","author":"Fux R","year":"2005","unstructured":"Fux R, M\u00f6rike K, Pr\u00f6hmer AM, et al.. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther. 2005, 78:378-87. 10.1016\/j.clpt.2005.07.004","journal-title":"Clin Pharmacol Ther"},{"key":"ref30","article-title":"TOPROL-XL (metoprolol succinate) [package insert]. Wilmington, DE: AstraZeneca","author":"AstraZeneca","year":"2016","unstructured":"AstraZeneca. TOPROL-XL (metoprolol succinate). AstraZeneca, Wilmington, DE; 2016."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 updated AGS beers criteria\u00ae for potentially inappropriate medication use in older adults","volume":"67","author":"The American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","unstructured":"The American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS beers criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019, 67:674-94. 10.1111\/jgs.15767","journal-title":"J Am Geriatr Soc"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon N","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017, 17:230. 10.1186\/s12877-017-0621-2","journal-title":"BMC Geriatr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/81096-idiopathic-symptoms-resolved-by-pharmacogenomics-enriched-comprehensive-medication-management-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:08Z","timestamp":1707507428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/81096-idiopathic-symptoms-resolved-by-pharmacogenomics-enriched-comprehensive-medication-management-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.21834","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,2]]}}}